Clinical Trial Update: Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC) [Phase 2]

View source ↗

Summary

This is a Phase 2 trial comparing lenvatinib 24 mg/day versus 10 mg/day in patients with radioactive iodine–resistant differentiated thyroid cancer, currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Thyroid Cancer, Cancer of the Thyroid | Phase 2 | Status: RECRUITING